Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05019625 · ClinicalTrials.gov registry record
Biomarker Development for Muscular Dystrophies
A clinical trial of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 465
- Enrollment target
- 5
- Study locations
NCT05019625 is a study of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 465 participants, above the 403-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (15% higher). The trial reports 5 study locations across 3 states.
The verdict
NCT05019625, a study of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 465 participants
- Enrollment target
- 5
- Study locations
Study Summary
Current methods of measuring the response to new treatments for muscular dystrophies involve the examination of small pieces of muscle tissue called biopsies. The investigators are interested in finding less invasive methods that reduce the need for muscle biopsies. The purpose of this research is to learn about the possibility of detecting and measuring the activity and severity of muscular dystrophies by examining a urine sample and a blood sample, and some muscles in the arms and legs using tests called ultrasound and electrical impedance myography; both tests are painless and non-invasive. The information that is gathered from this study may help to evaluate, prevent, diagnose, treat, and improve the understanding of human muscle diseases.
Conditions Studied
Study Locations (5)
Massachusetts
- Boston Children's Hospital - Boston
- Brigham and Women's Hospital - Boston
- Massachusetts General Hospital - Boston
North Carolina
- Wake Forest University - Winston-Salem
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 465 participants |
| Start Date | 2015-02-20 |
| Est. Completion | 2028-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05019625
The ClinicalTrials.gov registry entry for NCT05019625 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 465 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 403-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (15% higher). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Duchenne Muscular Dystrophy appearing as the primary indexed condition, and to 0 interventions.
NCT05019625 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05019625 about?
NCT05019625 is a clinical study titled "Biomarker Development for Muscular Dystrophies". Current methods of measuring the response to new treatments for muscular dystrophies involve the examination of small pieces of muscle tissue called biopsies. The investigators are interested in finding less invasive methods that reduce the need for muscle biopsies. The purpose of this research is t...
What is the current status of trial NCT05019625?
This trial is currently recruiting. The enrollment target is 465 participants. The study started on 2015-02-20. Estimated completion is 2028-06.
What conditions does trial NCT05019625 study?
This clinical trial studies the following conditions: Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Myotonic Dystrophy, Facioscapulohumeral Muscular Dystrophy.
Who is sponsoring clinical trial NCT05019625?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05019625 being conducted?
This trial has 5 study locations across Massachusetts, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Duchenne Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
RECRUITING · Phase 1
-
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
RECRUITING · Phase 2
-
Once Weekly Infant Corticosteroid Trial for DMD
RECRUITING · Phase 4
-
The Duchenne Registry
RECRUITING
Explore more on PlainTrial
Duchenne Muscular Dystrophy
All registered trials for this condition
Becker Muscular Dystrophy
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.